Corteva, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CTVA in the last 30 days.
See all $CTVA insider activity →South Africa's GMO Executive Council approved field trial permits for Corteva Agriscience's GM canola. Environmental groups oppose it, citing risks of chemical dependence and genetic contamination. Grain SA's CEO argues access to such technology is crucial for farmers' competitiveness. Trials will last three seasons, with strict containment measures.
Analysts from RBC Capital and others provided updates on Corteva (CTVA), Vale SA (VALE), and Ecolab (ECL). Corteva received a Buy rating with a $17.00 target, Vale a Hold with a $16.00 target, and Ecolab a Buy with a $337.00 target. Analyst consensus for Corteva is Strong Buy, Vale is Hold, and Ecolab is Strong Buy.
FMC stock dropped 33% due to a significant earnings downgrade by Citi, which also expects a modest negative reaction in Corteva shares. RBC Capital noted that FMC's Q3 outlook change risks its 2026 targets and may pressure Corteva. Corteva aims for $8.4B-$8.7B in annual sales by 2029 post-spin-off. FMC shares are down 62% in 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CTVA (Corteva, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CTVA coverage spans financial news, regulation and corporate actions.
The permit may lead to future commercial rollout but faces strong opposition, creating uncertainty.
Buy rating and lower target may support modest upside.
FMC stock dropped 33% due to a significant earnings downgrade by Citi, which also expects a modest negative reaction in Corteva shares. RBC Capital noted that FMC's Q3 outlook change risks its 2026 targets and may pressure Corteva. Corteva aims for $8.4B-$8.7B in annual sales by 2029 post-spin-off. FMC shares are down 62% in 2026.
The deal expands Corteva's access to gene-editing tools for humanitarian use, potentially enhancing its reputation and future market opportunities in emerging markets.
Legal injunction likely drags Corteva stock lower as investors price in uncertainty and restricted capital actions.
AlphAI scores every news story that mentions CTVA with an AI model for sentiment and relevance, and aggregates insider trades from Corteva, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
South Africa's GMO Executive Council approved field trial permits for Corteva Agriscience's GM canola. Environmental groups oppose it, citing risks of chemical dependence and genetic contamination. Grain SA's CEO argues access to such technology is crucial for farmers' competitiveness. Trials will last three seasons, with strict containment measures.
2 min readAnalysts from RBC Capital and others provided updates on Corteva (CTVA), Vale SA (VALE), and Ecolab (ECL). Corteva received a Buy rating with a $17.00 target, Vale a Hold with a $16.00 target, and Ecolab a Buy with a $337.00 target. Analyst consensus for Corteva is Strong Buy, Vale is Hold, and Ecolab is Strong Buy.
2 min readFMC stock dropped 33% due to a significant earnings downgrade by Citi, which also expects a modest negative reaction in Corteva shares. RBC Capital noted that FMC's Q3 outlook change risks its 2026 targets and may pressure Corteva. Corteva aims for $8.4B-$8.7B in annual sales by 2029 post-spin-off. FMC shares are down 62% in 2026.
1 min readICRISAT has secured a long-term licensing agreement for CRISPR-Cas9 technology with Corteva and The Broad Institute. The deal aims to accelerate the development of climate-resilient crops for smallholder farmers in Asia and Africa, enhancing productivity and nutritional quality. ICRISAT's Director General highlighted the transformative potential for food security and rural livelihoods.
1 min readCorteva, Inc. (CTVA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 1, 2026, 15 states and one sovereign commenced litigation in the United States District Court for the Southern District of Indiana (the “District Court”) challenging the separation of Corteva, Inc. (“Corteva” or the “Company”) and Vylor Inc. (“Vy
2 min readUBS maintained a Neutral rating on Corteva (CTVA) but lowered its price target from $90 to $15. Corteva's stock is overvalued by 35% according to GuruFocus, with a GF Value of $9.85. The company has a market cap of $8.88B and operates in the agriculture sector, focusing on seeds and crop protection.
2 min readCorteva Inc. is appealing a court order that temporarily blocks it from paying dividends or buying back stock. The order was granted to 15 states and a territory, and Corteva has paused the restrictions while seeking relief. The case involves the spinoff of Corteva's seed business.
1 min readCorteva split into two separate companies: New Corteva (crop protection) and Vylor (seeds). Shareholders received one Vylor share per Corteva share. The split aims to enhance focus and innovation. Corteva has an $11B crop protection pipeline and serves farmers in 110 countries.
3 min readUBS maintains a neutral rating on Corteva, citing easing generic competition but potential margin pressure from raw material inflation through 2027. The bank expects modest price increases, volume growth, and organic growth, with new products aiding 2028 and beyond. UBS sets a $15 price target, emphasizing the importance of cost pass-through for earnings.
1 min readDaniel S. Sullivan disclosed stock trades, including selling shares of Constellation Energy (CEG) and Exelon (EXC) in May 2023, and selling shares of Corteva (CTVA), Dow (DOW), IFF, Oracle (ORCL), and DuPont (DD) in early 2021. The transaction amounts ranged from $1,001 to $50,000.
1 min read
